Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target) (NETs-target)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04785066 |
Recruitment Status :
Recruiting
First Posted : March 5, 2021
Last Update Posted : August 28, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The functional prognosis of patients with ischaemic stroke treated by thrombolysis and thrombectomy is associated with complete reperfusion of the occluded artery defined by an mTICI 2C or 3 score at the end of thrombectomy. However, this complete reperfusion is only obtained in 60% of patients. Most often, incomplete reperfusion is due to the persistence of distal occlusions, which are inaccessible to mechanical thrombectomy. Drug treatment, combined with thrombectomy to increase the rate of complete reperfusion, would be a major advance in the management of these patients.
This is a non-randomized, monocentric, open-label, phase II trial to evaluate efficacy of dornase alfa intravenous administration in patients treated with intravenous thrombolysis and eligible for thrombectomy for ischemic stroke of the anterior circulation.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ischemic Stroke | Drug: Administration of dornase alfa | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 44 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of the Efficacy of Dornase Alfa (Pulmozyme®) on Arterial Recanalization in Post-thrombectomy Angiography in Patients With Ischemic Stroke by Thrombolysis and Eligible for Thrombectomy (NETs-target) |
Actual Study Start Date : | August 19, 2022 |
Estimated Primary Completion Date : | August 18, 2025 |
Estimated Study Completion Date : | November 18, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Study treatment
Administration of dornase alfa during intervention of thrombectomy
|
Drug: Administration of dornase alfa
Patient treated for a cerebral thrombectomy will be administred dornase alfa treatment by intravenous |
- Evaluate the efficacy of intravenous administration of dornase alfa (Pulmozyme®) on arterial recanalization in post-thrombectomy patients managed for ischemic stroke [ Time Frame: 3 months after procedure ]
Complete recanalization defined by a modified treatment in cerebral infarction (mTICI) 2C or 3 score at cerebral angiography one hour after the start of pulmozyme administration or at the end of the thrombectomy procedure (if procedure >1h).
- The grade 2C corresponds to : Near complete perfusion except for slow flow in a few distal cortical vessels, or presence of small distal cortical emboli.
- The grade 3 corresponds to: complete antegrade reperfusion of the previously occluded target artery ischemic territory, with absence of visualized occlusion in all distal branches
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Ischemic stroke by proximal intracranial occlusion (internal carotid artery, middle cerebral artery in its M1 or M2 segment) isolated from the anterior circulation eligible for cerebral thrombectomy.
- Transferred to the NRI block for a cerebral thrombectomy.
- Treated by thrombolysis intravenous (Aleplase or Tenecteplase) as recommanded by European stroke organisation
- With DWI-ASPECT score>5 to MRI
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Known allergy to Dornase alfa or one of its excipients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04785066
Contact: Jean-Philippe DESILLES | 0148036454 | jpdesilles@for.paris | |
Contact: Amélie Yavchitz | 0148036454 | ayavchitz@for.paris |
France | |
Hôpital Fondation Adolphe de Rothschild | Recruiting |
Paris, France, 75019 | |
Contact: Amélie YAVCHITZ, MD, PhD +33 1 48 03 64 54 ayavchitz@for.paris |
Responsible Party: | Fondation Ophtalmologique Adolphe de Rothschild |
ClinicalTrials.gov Identifier: | NCT04785066 |
Other Study ID Numbers: |
JDS_2021_5 |
First Posted: | March 5, 2021 Key Record Dates |
Last Update Posted: | August 28, 2023 |
Last Verified: | July 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Stroke Ischemic Stroke Cerebral Infarction Ischemia Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Vascular Diseases Cardiovascular Diseases Pathologic Processes Brain Infarction Brain Ischemia Infarction Necrosis |